Friday, 18 Oct 2019

You are here

Ixekizumab vs. Adalimumab in Psoriatic Arthritis

The Annals of Rheumatic Disease reports a psoriatic arthritis study where in ixekizumab was non-inferior to adalimumab for achievement of ACR50 responses but was superior to adalimumab for achievement of PASI100 by week 24.

The study aimed to compare ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and psoriatic skin disease after and inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARDs).

The 12 month study included 566 active PsA patients who were randomised (1:1) to either IXE or ADA in an open-label, head-to-head, blinded assessor clinical trial. The primary endpoint was a composite 6 mos. response measured by the ACR50 and a PASI100 - 100% improvement from baseline in the Psoriasis Area and Severity Index. 

The primary endpoint favored IXE (36%) over ADA (28%; p=0.036).  The difference was largely driven by skin superiority for IXE, as the ACR50 responses were similar (IXE: 51%, ADA: 47%), but the PASI100 responses favored IXE (IXE: 60%, ADA: 47%; p=0.001). IXE had greater response versus ADA in other secondary outcomes for PsA, including skin, nail, treat-to-target and quality-of-life outcomes. Serious adverse events were reported in 8.5% (ADA) and 3.5% (IXE) of patients.

IXE was superior to ADA in achievement of superior skin responses and equivalent to ADA in ACR50 outcomes. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Comorbidity Worsens Axial Spondyloarthritis

Comorbidities are common in patients with axial spondyloarthropathy (axSpA), and a recent study has shown that multimorbidity, the coexistence of 2 or more conditions, is associated with more severe disease than those without comorbidities.

One-Third of Psoriatic Arthritis Patients Will Need Joint Surgery

Dannish study has shown that one-third of psoriatic arthritis (PsA) will have joint surgery that that PsA patients have twice the rate of joint surgery when compared with the general population.

The Danish National Patient Registry was used in this cohort study of incident PsA patients and their future risk of joint surgery compared to a general population cohort (GPC) between 1995-2012).

FUTURE 5 - Secukinumab and Less Radiographic Progression in Psoriatic Arthritis

The FUTURE 5 trial studied the effect of secukinumab (SEC) on radiographic progression through 52 weeks in patients with active psoriatic arthritis (PsA) and found that SEC was clinically and radiographically superior to placebo (PBO). Patients received s.c. secukinumab 300 mg load (300 mg), 150 mg load (150 mg), 150 mg no load regimens or placebo at baseline, at weeks 1, 2 and 3 and every 4 weeks starting at week 4. The majority (87%) of patients enrolled at baseline remained in the study for 52 weeks.

NSAID Use Linked With Hypertension in Ankylosing Spondylitis

Continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) among patients with ankylosing spondylitis (AS) was associated with the development of incident hypertension, a prospective cohort study found.

Anti-IL-23 Beats IL-17 in Plaque Psoriasis

Lancet reports a head-to-head trial of antibodies against interleukin (IL)-23 and IL-17A in patients with moderate-to-severe psoriasis favored guselkumab with superior PASI 90 responses at week 48 (compared to secukinumab).